# Evaluating Efficacy and Safety of Danazol in Severe Hematologic or Pulmonary Disease Related to Telomeropathy

> **NCT03710356** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 40 (estimated)

## Conditions studied

- Telomere Shortening
- Telomere Length, Mean Leukocyte

## Interventions

- **DRUG:** Danazol 200 MG

## Key facts

- **NCT ID:** NCT03710356
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-10-20
- **Primary completion:** 2021-10-20
- **Final completion:** 2022-10-20
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2018-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03710356

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03710356, "Evaluating Efficacy and Safety of Danazol in Severe Hematologic or Pulmonary Disease Related to Telomeropathy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03710356. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*